Post hoc magnetic resonance imaging cannot justify the conclusions of WHIMS

Gynecological Endocrinology

Volumn 26, Issue 6, 2010, Pages 391-392

  Naftolin, Frederick ^a   King, Jennifer ^b   Morrison, John H ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN PLUS GESTAGEN; GESTAGEN; MEDROXYPROGESTERONE; PLACEBO; UNCLASSIFIED DRUG;

AGING; BRAIN SIZE; CARBOHYDRATE METABOLISM; CLINICAL PRACTICE; CLINICAL STUDY; COGNITION; COGNITIVE DEFECT; DEMENTIA; EDITORIAL; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HORMONAL THERAPY; LIPOPROTEIN METABOLISM; MEMORY; MENOPAUSE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; WOMEN'S HEALTH; WOMEN'S HEALTH INITIATIVE MEMORY STUDY;

AGED; AGED, 80 AND OVER; BRAIN; COGNITION DISORDERS; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MEDROXYPROGESTERONE ACETATE;

EID: 77952121747     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003630229     Document Type: Editorial

References (8)

1. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study - a randomized controlled trial. JAMA 2003;289: 2651-2662.
2. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
3. Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: the WHIMSMRI Study. Neurology 2009;72:135-142.
4. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-695.
5. Tan O, Harman SM, Naftolin F. What can we learn from design faults in the Women's Health Initiative randomized clinical trial? Bull NYU Hosp Jt Dis 2009;67:226-229.
6. Nilsen J, Deng J, Brinton RD. Impact of clinically relevant progestins on the neural effects of estradiol and the signaling pathways involved. Drug News Perspect 2005; 18:545-553.
7. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184: 255-263.
8. Darney PD. The androgenicity of progestins. Am J Med 1995; 98:104S-110S.